216 related articles for article (PubMed ID: 24034838)
1. Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma.
Madhunapantula SV; Sharma A; Gowda R; Robertson GP
Pigment Cell Melanoma Res; 2013 Nov; 26(6):886-99. PubMed ID: 24034838
[TBL] [Abstract][Full Text] [Related]
2. Targeting sphingosine kinase-1 to inhibit melanoma.
Madhunapantula SV; Hengst J; Gowda R; Fox TE; Yun JK; Robertson GP
Pigment Cell Melanoma Res; 2012 Mar; 25(2):259-74. PubMed ID: 22236408
[TBL] [Abstract][Full Text] [Related]
3. Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma.
Miyashita K; Kawakami K; Nakada M; Mai W; Shakoori A; Fujisawa H; Hayashi Y; Hamada J; Minamoto T
Clin Cancer Res; 2009 Feb; 15(3):887-97. PubMed ID: 19188159
[TBL] [Abstract][Full Text] [Related]
4. GSK3α/β: A Novel Therapeutic Target for Neuroendocrine Tumors.
Aristizabal Prada ET; Weis C; Orth M; Lauseker M; Spöttl G; Maurer J; Grabowski P; Grossman A; Auernhammer CJ; Nölting S
Neuroendocrinology; 2018; 106(4):335-351. PubMed ID: 28968593
[TBL] [Abstract][Full Text] [Related]
5. Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.
Sharma A; Madhunapantula SV; Gowda R; Berg A; Neves RI; Robertson GP
Am J Pathol; 2013 Apr; 182(4):1151-62. PubMed ID: 23416158
[TBL] [Abstract][Full Text] [Related]
6. GSK3β inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation.
John JK; Paraiso KH; Rebecca VW; Cantini LP; Abel EV; Pagano N; Meggers E; Mathew R; Krepler C; Izumi V; Fang B; Koomen JM; Messina JL; Herlyn M; Smalley KS
J Invest Dermatol; 2012 Dec; 132(12):2818-27. PubMed ID: 22810307
[TBL] [Abstract][Full Text] [Related]
7. New methods to control neuroblastoma growth.
Dent P
Cancer Biol Ther; 2014 May; 15(5):481-2. PubMed ID: 24618834
[TBL] [Abstract][Full Text] [Related]
8. Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth.
Carter YM; Kunnimalaiyaan S; Chen H; Gamblin TC; Kunnimalaiyaan M
Cancer Biol Ther; 2014 May; 15(5):510-5. PubMed ID: 24521712
[TBL] [Abstract][Full Text] [Related]
9. Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma.
Abe K; Yamamoto N; Domoto T; Bolidong D; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Inatani H; Aoki Y; Higuchi T; Taniguchi Y; Yonezawa H; Araki Y; Aiba H; Minamoto T; Tsuchiya H
Cancer Sci; 2020 Feb; 111(2):429-440. PubMed ID: 31808966
[TBL] [Abstract][Full Text] [Related]
10. Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression.
Kunnimalaiyaan S; Gamblin TC; Kunnimalaiyaan M
HPB (Oxford); 2015 Sep; 17(9):770-6. PubMed ID: 26147011
[TBL] [Abstract][Full Text] [Related]
11. GSK3β suppression inhibits MCL1 protein synthesis in human acute myeloid leukemia cells.
Lee YC; Shi YJ; Wang LJ; Chiou JT; Huang CH; Chang LS
J Cell Physiol; 2021 Jan; 236(1):570-586. PubMed ID: 32572959
[TBL] [Abstract][Full Text] [Related]
12. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma.
Wu X; Stenson M; Abeykoon J; Nowakowski K; Zhang L; Lawson J; Wellik L; Li Y; Krull J; Wenzl K; Novak AJ; Ansell SM; Bishop GA; Billadeau DD; Peng KW; Giles F; Schmitt DM; Witzig TE
Blood; 2019 Jul; 134(4):363-373. PubMed ID: 31101621
[TBL] [Abstract][Full Text] [Related]
13. Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.
Atkinson JM; Rank KB; Zeng Y; Capen A; Yadav V; Manro JR; Engler TA; Chedid M
PLoS One; 2015; 10(4):e0125028. PubMed ID: 25915038
[TBL] [Abstract][Full Text] [Related]
14. The Glycogen Synthase Kinase 3α and β Isoforms Differentially Regulates Interleukin-12p40 Expression in Endothelial Cells Stimulated with Peptidoglycan from Staphylococcus aureus.
Cortés-Vieyra R; Silva-García O; Oviedo-Boyso J; Huante-Mendoza A; Bravo-Patiño A; Valdez-Alarcón JJ; Finlay BB; Baizabal-Aguirre VM
PLoS One; 2015; 10(7):e0132867. PubMed ID: 26200352
[TBL] [Abstract][Full Text] [Related]
15. Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFκB via suppression of GSK-3β expression.
Ban JO; Oh JH; Son SM; Won D; Song HS; Han SB; Moon DC; Kang KW; Song MJ; Hong JT
Cancer Biol Ther; 2011 Aug; 12(4):288-96. PubMed ID: 21613824
[TBL] [Abstract][Full Text] [Related]
16. GSK3β isoform-selective regulation of depression, memory and hippocampal cell proliferation.
Pardo M; Abrial E; Jope RS; Beurel E
Genes Brain Behav; 2016 Mar; 15(3):348-55. PubMed ID: 26749572
[TBL] [Abstract][Full Text] [Related]
17. Glycogen synthase kinase 3 alpha and 3 beta have distinct functions during cardiogenesis of zebrafish embryo.
Lee HC; Tsai JN; Liao PY; Tsai WY; Lin KY; Chuang CC; Sun CK; Chang WC; Tsai HJ
BMC Dev Biol; 2007 Aug; 7():93. PubMed ID: 17683539
[TBL] [Abstract][Full Text] [Related]
18. Discrete functions of GSK3α and GSK3β isoforms in prostate tumor growth and micrometastasis.
Gao F; Al-Azayzih A; Somanath PR
Oncotarget; 2015 Mar; 6(8):5947-62. PubMed ID: 25714023
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation.
Kotliarova S; Pastorino S; Kovell LC; Kotliarov Y; Song H; Zhang W; Bailey R; Maric D; Zenklusen JC; Lee J; Fine HA
Cancer Res; 2008 Aug; 68(16):6643-51. PubMed ID: 18701488
[TBL] [Abstract][Full Text] [Related]
20. GSK3beta inhibition promotes melanogenesis in mouse B16 melanoma cells and normal human melanocytes.
Bellei B; Flori E; Izzo E; Maresca V; Picardo M
Cell Signal; 2008 Oct; 20(10):1750-61. PubMed ID: 18602000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
